BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Authors » Lynn Yoffee

Lynn Yoffee

lynn.yoffee@clarivate.com
Articles

ARTICLES

Inovio Biomedical miniaturizes vaccine electroporation device

Feb. 1, 2010
By Lynn Yoffee
Just a little zap and temporary pores open. Inovio Biomedical (San Diego) is banking on this process, known as electroporation, to substantially change vaccine delivery. It has just unveiled a new clinical-grade, miniaturized device designed to deliver a variety of DNA vaccines, opening the door to push its healthy pipeline of new-style preventive and therapeutic vaccines into human trials. (Medical Device Daily)
Read More

Halt's fibroid device, procedure to make other treatments 'irrelevant'

Jan. 28, 2010
By Lynn Yoffee

IBM tech finds brain aneurysms better than manual approach

Jan. 27, 2010
By Lynn Yoffee
The computerized "eye" is better than any human eye. That theory has been proven positive when it comes to spotting brain aneurysms. An IBM (Armonk, New York) and Mayo Clinic (Rochester, New York) alliance has yielded analytics technology with a 95% accuracy rate in detecting aneurysms, compared with a 70% rate for standard manual interpretation. (Medical Device Daily)
Read More

Rocking embryos via microfluidic device improves IVF success

Jan. 22, 2010
By Lynn Yoffee

Lantheus Medical launches first imaging agent for use with MRA

Jan. 21, 2010
By Lynn Yoffee

Study: Oncotype DX is changing breast cancer treatment choices

Jan. 18, 2010
By Lynn Yoffee

MarginProbe aims to reduce breast cancer reoperations

Jan. 15, 2010
By Lynn Yoffee

First hand-held OCT device IDs blinding condition in preemies

Jan. 14, 2010
By Lynn Yoffee

Philips launches enhanced BiPAP for complicated form of sleep apnea

Jan. 11, 2010
By Lynn Yoffee
For up to 10% of people with sleep disordered breathing, standard CPAP machines won't do the trick. Royal Philips Electronics (Murrysville, Pennsylvania) has launched a new, enhanced version BiPAP autoSV Advanced for patients who have both obstructive sleep apnea and central sleep apnea as well as Cheyne-Stokes Respiration, a periodic breathing disorder. (Medical Device Daily)
Read More

TORS dramatically changes head, neck cancer outcomes

Jan. 8, 2010
By Lynn Yoffee
View All Articles by Lynn Yoffee

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing